secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001601485-24-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Therapeutics reports FY2023 net loss $35.2M; cash boosted by $6M private placement
--------------------------------------------------------------------------------

- Net loss of $35.2M for FY2023 vs $28.2M in FY2022; diluted EPS -$6.96 vs -$89.27 (reverse-merger impact).
- Cash and cash equivalents $12.9M at Dec 31, 2023; $6.0M private placement closed in March 2024.
- ELI-002 2P Phase 1a data in Nature Medicine: 84% T cell response, 24% biomarker clearance, median RFS 16.33 months.
- Phase 2 randomized trial of ELI-002 7P in PDAC started; enrollment expected to complete Q4 2024.
- Initial clinical data from ELI-002 7P Phase 1 trial anticipated in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/0001601485-24-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000021/angn-20240329.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer